The antiangiogenic mechanisms of action of thalidomide is the inhibition of VEGF, bFGF, and TGF-β signaling, which has been shown to contribute to the anti-inflammatory and anti-tumor effects of the drug [9, 25–27]. Here, FGF2 is linked to neoplasm.